Keytruda Now FDA-Approved for Patients with Melanoma
The KEYNOTE-054 Phase 3 clinical trial (NCT02362594) showed that the immune checkpoint inhibitor drug Keytruda decreased the risk of melanoma recurrence or death by 43% in comparison to a placebo drug. The drug has thus been approved by the U.S. Food and Drug Administration (FDA) to treat patients with stage-3 melanoma (cancer has spread to […]
Continue readingAdvancements in Immunotherapy Changing the Landscape of Cancer Treatment
Cancer patients have a better chance at beating diseases with the help of immunotherapy, a type of cancer treatment, as studies are now showing. Two new immunotherapy drugs have recently been approved by the Food and Drug Administration last March. One of the immunotherapies approved is Keytruda, which is made to treat Hodgkin’s lymphoma for […]
Continue reading